‘‘(A) catalyze support for research and de-
velopment of new tools to prevent, diagnose, 
treat, and control TB worldwide, particularly to 
reduce the incidence of, and mortality from, all 
forms of drug-resistant TB; 
‘‘(B) ensure United States programs and 
activities focus on finding individuals with ac-
tive TB disease and provide quality diagnosis 
and treatment, and reaching those at high risk 
with preventive therapy; and 
‘‘(C) ensure coordination among relevant 
United States Government agencies, including 
the Department of State, the Centers for Dis-
ease Control and Prevention, the National In-
stitutes of Health, the Biomedical Advanced 
Research and Development Authority, the Food 
and Drug Administration, the National Science 
Foundation, 
the 
Department 
of 
Defense 
(through its Congressionally Directed Medical 
Research Program), and other Federal agencies 
that engage in international TB activities to en-
sure accountability and transparency, reduce 
duplication of efforts and ensure appropriate in-
tegration and coordination of TB services into 
other United States-supported health programs. 
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(g) PRIORITY TO END TB STRATEGY.—In fur-
nishing assistance under subsection (d), the President 
shall give priority to— 
‘‘(1) building and strengthening TB programs 
to increase diagnosis and treatment of everyone who 
is sick with TB, and ensuring such individuals have 
access to quality diagnosis and treatment; 
‘‘(2) direct, high-quality integrated services for 
all forms of TB, as described by the World Health 
Organization, which call for the coordination of ac-
tive case finding, treatment of all forms of TB dis-
ease and infection, patient support, and TB preven-
tion; 
‘‘(3) individuals co-infected with HIV and other 
co-morbidities, and other individuals with TB who 
may be at risk of stigma; 
‘‘(4) strengthening the capacity of health sys-
tems to detect, prevent, and treat TB, including 
MDR–TB and XDR–TB, as described in the latest 
international guidance related to TB; 
‘‘(5) research and development of innovative 
diagnostics, drug therapies, and vaccines, and pro-
gram-based research; 
‘‘(6) the Stop Tuberculosis Partnership’s Global 
Drug Facility, and the Global Alliance for Tuber-
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS
culosis Drug Development, and other organizations 
promoting the development of new products and 
drugs for TB; and 
‘‘(7) ensuring TB programs can serve as key 
platforms for supporting national respiratory pan-
demic response against existing and new infectious 
respiratory disease. 
‘‘(h) ASSISTANCE FOR THE WORLD HEALTH ORGA-
NIZATION
AND
THE STOP TUBERCULOSIS PARTNER-
SHIP.—In carrying out this section, the President, acting 
through the Administrator of the United States Agency 
for International Development, is authorized to provide re-
sources to the World Health Organization and the Stop 
Tuberculosis Partnership to improve the capacity of coun-
tries with high burdens or rates of TB and other affected 
countries to implement the End TB Strategy, the Stop 
TB Global Plan to End TB, their own national strategies 
and plans, other global efforts to control MDR–TB and 
XDR–TB, and, to leverage the contributions of other do-
nors for such activities. 
‘‘(i) ANNUAL REPORT ON TB ACTIVITIES.—Not later 
than December 15 of each year until the goals specified 
in subsection (b)(1) are met, the President shall submit 
an annual report to the appropriate congressional commit-
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS
tees that describes United States foreign assistance to 
control TB and the impact of such efforts, including— 
‘‘(1) the number of individuals with active TB 
disease that were diagnosed and treated, including 
the rate of treatment completion and the number re-
ceiving patient support; 
‘‘(2) the number of persons with MDR–TB and 
XDR–TB that were diagnosed and treated, includ-
ing the rate of completion, in countries receiving 
United States bilateral foreign assistance for TB 
control programs; 
‘‘(3) the numbers of people trained by the 
United States Government in TB surveillance and 
control; 
‘‘(4) the number of individuals with active TB 
disease identified as a result of engagement with the 
private sector and other nongovernmental partners 
in countries receiving United States bilateral foreign 
assistance for TB control programs; 
‘‘(5) a description of the collaboration and co-
ordination of United States anti-TB efforts with the 
World Health Organization, the Stop TB Partner-
ship, the Global Fund to Fight AIDS, Tuberculosis 
and Malaria, and other major public and private en-
tities; 
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(6) a description of the collaboration and co-
ordination among the United States Agency for 
International Development and other United States 
offices and agencies, including the Centers for Dis-
ease Control and Prevention and the Office of the 
Global AIDS Coordinator, for the purposes of com-
bating TB; 
‘‘(7) the constraints on implementation of pro-
grams posed by health workforce shortages, health 
system limitations, other challenges to successful im-
plementation and strategies to address such con-
straints; 
‘‘(8) a breakdown of expenditures for patient 
services supporting TB diagnosis, treatment, and 
prevention, including procurement of drugs and 
other commodities, drug management, training in di-
agnosis and treatment, health systems strengthening 
that directly impacts the provision of TB services, 
and research; and 
‘‘(9) for each country, and when practicable, 
each project site receiving bilateral United States as-
sistance for the purpose of TB prevention, treat-
ment, and control— 
‘‘(A) a description of progress toward the 
adoption and implementation of the most recent 
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS
World Health Organization guidelines to im-
prove diagnosis, treatment, and prevention of 
TB for adults and children, disaggregated by 
sex, including the proportion of health facilities 
that have adopted the latest World Health Or-
ganization guidelines on strengthening moni-
toring systems and preventative, diagnostic, and 
therapeutic methods, including the use of rapid 
diagnostic tests and orally administered TB 
treatment regimens; 
‘‘(B) the number of individuals screened 
for TB disease and the number evaluated for 
TB infection using active case finding outside 
of health facilities; 
‘‘(C) the number of individuals with active 
TB disease that were diagnosed and treated, in-
cluding the rate of treatment completion and 
the number receiving patient support; 
‘‘(D) the number of adults and children, 
including people with HIV and close contacts, 
who are evaluated for TB infection, the number 
of adults and children started on treatment for 
TB infection, and the number of adults and 
children 
completing 
such 
treatment, 
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS
disaggregated by sex and, as possible, income or 
wealth quintile; 
‘‘(E) the establishment of effective TB in-
fection control in all relevant congregant set-
tings, including hospitals, clinics, and prisons; 
‘‘(F) a description of progress in imple-
menting measures to reduce TB incidence, in-
cluding actions— 
‘‘(i) to expand active case finding and 
contact tracing to reach vulnerable groups; 
and 
‘‘(ii) to expand TB preventive ther-
apy, engagement of the private sector, and 
diagnostic capacity; 
‘‘(G) a description of progress to expand 
diagnosis, prevention, and treatment for all 
forms of TB, including in pregnant women, 
children, and individuals and groups at greater 
risk of TB, including migrants, prisoners, min-
ers, people exposed to silica, and people living 
with HIV/AIDS, disaggregated by sex; 
‘‘(H) the rate of successful completion of 
TB 
treatment 
for 
adults 
and 
children, 
disaggregated by sex, and the number of indi-
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS
viduals receiving support for treatment comple-
tion; 
‘‘(I) the number of people, disaggregated 
by sex, receiving treatment for MDR–TB, the 
proportion of those treated with the latest regi-
mens endorsed by the World Health Organiza-
tion, factors impeding scale up of such treat-
ment, and a description of progress to expand 
community-based MDR–TB care; 
‘‘(J) a description of TB commodity pro-
curement 
challenges, 
including 
shortages, 
stockouts, or failed tenders for TB drugs or 
other commodities; 
‘‘(K) the proportion of health facilities 
with specimen referral linkages to quality diag-
nostic networks, including established testing 
sites and reference labs, to ensure maximum ac-
cess and referral for second line drug resistance 
testing, and a description of the turnaround 
time for test results; 
‘‘(L) the number of people trained by the 
United States Government to deliver high-qual-
ity TB diagnostic, preventative, monitoring, 
treatment, and care services; 
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(M) a description of how supported activi-
ties are coordinated with— 
‘‘(i) country national TB plans and 
strategies; and 
‘‘(ii) TB control efforts supported by 
the Global Fund to Fight AIDS, Tuber-
culosis, and Malaria, and other inter-
national assistance programs and funds, 
including in the areas of program develop-
ment and implementation; and 
‘‘(N) for the first 3 years of the report re-
quired under this subsection, a section that de-
scribes the progress in recovering from the neg-
ative impact of COVID–19 on TB, including 
whether there has been the development and 
implementation of a comprehensive plan to en-
sure TB activities recover from diversion of re-
sources, the continued use of bidirectional TB– 
COVID testing, and progress on increased diag-
nosis and treatment of active TB. 
‘‘(j) ANNUAL REPORT ON TB RESEARCH AND DE-
VELOPMENT.—The President, acting through the Admin-
istrator of the United States Agency for International De-
velopment, and in coordination with the National Insti-
tutes of Health, the Centers for Disease Control and Pre-
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS
vention, the Biomedical Advanced Research and Develop-
ment Authority, the Food and Drug Administration, the 
National Science Foundation, and the Office of the Global 
AIDS Coordinator, shall submit an annual report to Con-
gress that— 
‘‘(1) describes current progress and challenges 
to the development of new tools for the purpose of 
TB prevention, treatment, and control; 
‘‘(2) identifies critical gaps and emerging prior-
ities for research and development, including for 
rapid and point-of-care diagnostics, shortened treat-
ments and prevention methods, and vaccines; and 
‘‘(3) describes research investments by type, 
funded entities, and level of investment. 
‘‘(k) EVALUATION REPORT.—Not later than 2 years 
after the date of the enactment of the End Tuberculosis 
Now Act of 2022, and every 5 years thereafter until 2035, 
the Comptroller General of the United States shall submit 
a report to the appropriate congressional committees that 
evaluates the performance and impact on TB prevention, 
diagnosis, treatment, and care efforts that are supported 
by United States bilateral assistance funding, including 
recommendations for improving such programs.’’. 
Æ 
VerDate Sep 11 2014 
18:00 Sep 09, 2022
Jkt 029200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6301
E:\BILLS\H8654.IH
H8654
pamtmann on DSKBC07HB2PROD with BILLS